Bendamustine
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Fred Hutchinson Cancer CenterSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
25 Active assets in the Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Daunorubicin National Cancer Institute (NCI) | Phase 3 | BBB |
ETOPOSIDE M.D. Anderson Cancer Center | Phase 3 | BBB |
Cytosin-Arabinosid Alice Mims | Phase 3 | BBB |
Idarubicine Bruno C. Medeiros | Phase 2 | BBB |
Cyclophosphamide M.D. Anderson Cancer Center | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Bendamustine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →